Background and Objectives: Abdominal metastases (AM) from soft tissue sarcoma (STS) are rare and prognosis is poor. The aims of the study were to (a) identify risk factors for the development of AM and to (b) investigate the outcome of AM-patients. Methods: Seven-hundred-sixty-nine STS-patients with localised disease at diagnosis treated at three tumour centres (2000-2016) were retrospectively included (409 males; mean age, 55.6 years [range, 8-96 years]; median follow-up, 4.1 years [interquartile-range, 2.5-6.6 years]). Results: Two-hundred-two patients (26.3%) developed secondary metastases, and 24 of them AM (3.1%). Ten patients developed first AM (FAM) after a mean of 2.4 years and 14 patients late AM (LAM, after being diagnosed with metastases to other sites) after a mean of 2.0 years. Patients with liposarcoma had a significantly higher risk of developing AM (P = .007), irrespective of grading. There was no difference in postmetastasis-survival (PMS) between patients with AM at any time point and those with metastases to other sites (P = .585). Patients with LAM or FAM showed no difference in post-abdominal-metastasis-survival (P = .884).
prognosis with 2-year survival rates of 43%. 7 Diagnosis can be difficult as AM may be asymptomatic for a long time or may only cause vague discomfort. 8 Symptoms involve intestinal obstruction, abdominal pain, or gastrointestinal bleeding. 8 Since these very symptoms can also represent side effects from chemotherapy (CTX) or pain management, they can be easily misinterpreted. 6, 8 There is no clear consensus how to follow-up patients with localised STS following surgical resection, with different studies describing different follow-up regimes. [9] [10] [11] The current ESMO guidelines 12 suggest that STS-patients should be followed-up every 3 to 4 months for the first 3 years, then bi-annually for the following 2 years and thereafter annually by chest-X-rays and/or computed tomography-scan (CT-scan) of the lungs. However, the impact of regular abdominal CT-scans in follow-up remains unclear. 12 Three studies have been published so far on the topic of AM of STS. 7, 13, 14 However, the number of patients with AM identified in these studies was relatively low and more importantly they did not distinguish between patients with AM as the first metastatic manifestation and those with AM developing after other metastases had occurred, therefore leaving many clinical questions unanswered.
Incidence of AM, risk factors for their development, diagnostic tools and impact on patient survival were analysed in the present retrospective multi-centre study. The aims of the study were to (a) to investigate the outcome of these patients in comparison to STS-patients with metastases to other sites and those without metastases and (b) to identify factors associated with a higher risk for developing AM.
| MATERIALS AND METHODS
We performed a retrospective analysis of the files of 769 patients who had been diagnosed with a primary localised extremity STS (G1-G3) between January 2000 and May 2016 at three tertiary tumour centres.
Four-hundred-nine patients were male (53.2%) and 360 were female (46.8%). The mean age of all patients was 55.6 years (range, 8-96 years).
Median follow-up was 4.1 years (IQR, 2.5-6.6 years).
Data was collected by reviewing medical records, such as pathology and radiology reports, outpatient records and medical charts. Time to secondary metastasis (SM) and first abdominal metastasis (FAM) was calculated from date of definite surgery to the first radiological verification of a metastatic focus (eg, MRI, CT-scan). 
| Statistical analysis
All statistical analyses were performed with the Stata software version 15.1 (StataCorp, TX). Means and medians were calculated for normally and non-normally distributed data using t-tests and Mann-Whitney-U-tests, respectively. Comparisons between groups were made using χ 2 tests. Kaplan-Meier estimates and Cox-regression models were used to estimate outcome variables, providing hazard ratios (HRs), 95% confidence intervals (95%CI) and P values.
Considering that only two patients with AM underwent additional surgery, subgroup analysis to assess the effect of metastasectomy on PMS in this group of patients was not performed. Furthermore, the multivariate Cox-regression analysis was limited to two factors, in accordance with the 'one in ten rule'. 16 All P values are two-sided; a P value of <0.05 was considered statistically significant.
| RESULTS
Two-hundred-two patients (26.3%) developed SM after a median of 15 months (IQR, 10-29 months). Demographic features and tumour as well as treatment specific details of patients with and without SM are depicted in Table 1 .
Taking into account all metastatic foci developing during the course of the disease, the most common location was the lung (n = 114), followed by bone (n = 32) and regional as well as distant lymph nodes (n = 27; Figure 1 ). Rare locations included the pericard/ endocard as well as the skin in four cases, the subcutis in three and the meninges in two cases.
Twenty-four patients developed AMs during the course of disease (3.1%), including 13 hepatic, three intestinal, two pancreatic and two peritoneal metastases. Further four patients had multiple intestinal metastases, of whom two also had metastatic foci in the retroperitoneum.
Ten patients presented with a FAM after a mean of 2.4 years (range, 7 months to 8.3 years) and 14 patients a LAM, after having developed a primary metastasis to another site. In the latter case, the meantime to LAM from the development of SM was 2.0 years (range, 1 month to 3.6 years). Moreover, hepatic FAM (n = 5) showed no tendency to develop earlier than FAM at other sites (n = 5; 17.1 vs 10.1 months; ttest P = .793). 
| Diagnostic pathway

| Treatment
| Risk factors for abdominal metastases
Of those 24 patients with AM, 11 had originally been diagnosed with liposarcoma as the underlying histological subtype, four with UPS, three with leiomyosarcoma, one with myxofibrosarcoma and five with a miscellaneous histology (χ 2 test; P = .178). Patients with liposarcomas developed FAM significantly more often than patients with other histologies (P = .016; Figure 2 ). Patients with myxoid liposarcoma had a significantly higher risk of developing FAM in comparison to the remaining histological subtypes pooled together in our patient cohort ( Table 2 ).
In the multivariate analysis, histological subtype only (liposarcoma vs others; P = .007) could be identified as an independent negative prognostic parameter regarding the development of AM as the first metastatic manifestation, irrespective of grading (Table 3 ).
| Outcome
At last follow-up, 523 patients were alive without (68.0%) and 67 alive with disease (8.7%). One-hundred-nineteen patients had died of STS (15.5%), and 57 due to other causes (7.4%), whereas in four patients the cause of death remained unknown (0.4%). Depending on their metastasis status, nine patients with AM (37.5%), 86 patients with SM (51.1%) and 497 patients without metastases were still alive (87.8%).
Patients without SM had a significantly better OS than patients with SM (log-rank P < .0001; Figure 3 ). There were no differences in PMS between patients with AM at any time point and patients with SM other than AM (P = .585; Figure 4 ). Patients undergoing surgery for their metastasis had a significantly better PMS than patients Interestingly, there was also no difference in PAMS between patients with FAM and those with LAM (log-rank P = .884),
suggesting that occurrence of AM at any time point similarly reduces survival probability. Additionally, PAMS did not significantly differ between patients with liver metastases vs AM to other sites (HR, 1.610; 95%CI, 0.537-8.833; P = .395).
| DISCUSSION
STS metastasise most commonly via the bloodstream to the lungs. 17 AM, on the other hand, are extremely uncommon. 8 Few case reports and studies have been published, describing the course of patients with abdominal or retroperitoneal metastases from STS. 7, 13, 14, [18] [19] [20] These studies either included relatively low numbers of patients with AM or did not describe factors associated with a higher risk of developing AM in a time-dependent manner.
Thompson et al 21 described 140 STS-patients who were screened with CT-scans of the abdomen, and found that a total of four patients (2.9%) developed AM. 21 In another single-centre study, 19 AMs developing during the course of disease were observed in a group of 2127 STS (<1%). 7 In our cohort, 24 out of 769 patients with localised extremity and trunk STS developed AMs-most commonly to the liverresulting in a total frequency of 3.1%. This discrepancy may be explained by the fact that in our collective, most patients with AM were diagnosed by CT-scans (followed by ultrasonography), whilst in the study by Behranwala et al, 7 the use of abdominal CT-scans was not clearly described. Therefore, some AM may have remained undiagnosed in that study, explaining the lower rate.
Raising the question why AM from STS are extremely rare, one has to look at to basic research; according to two experimental studies by Skubitz et al, 22, 23 STS have different metastatic propensities based on their gene expression patterns. This suggests that not only the histological subtype, tumour size and grading have an influence on the propensity of STS-metastasis to occur, but also the individual genetic profile of STS most probably results in a different affinity to specific tissues.
Assuming that the affinity of STS to viscera is low, the time In our study, patients with liposarcomas as the underlying histological subtype had a significantly higher risk of developing AM, irrespective of grading. This is corresponding to observations made by Behranwala et al 7 and Lev-Chelouche et al, 6 in whose studies six out of 19 patients (myxoid subtype) and four out of 10 patients with AM, respectively, had liposarcomas as the underlying histotype. 6, 7 In our collective, patients with liposarcoma NOS, a myxoid or pleomorphic subtype had an equally high risk of developing AM. Of note, myxoid liposarcomas tend to metastasise at higher rates to sites other than the lung (including bone and abdomen/retroperitoneum) in comparison to most STS subtypes. 7, 24 This observation could be confirmed in the present study, with myxoid liposarcoma-patients having significantly higher risks of developing AM as compared with all other histologies pooled together. However, we did not find a higher risk of AM for myxoid liposarcoma-patients when compared to other liposarcoma subtypes,
indicating that at least in the frequency of abdominal surveillance (ie, CT-scans, sonography), no difference between the liposarcoma subtypes should be made.
The development of AMs at any time point was associated with a similar reduction in survival probability in our collective. This suggests that once STS gain affinity to the viscera, they have already converted into more aggressive tumours.
A recent study has shown that surgical resection of STSmetastases, in general, may be associated with an improved survival outcome, irrespective of confounding factors. 25 In that study, however, most metastases were located in the lungs and soft tissues rather than the abdomen. In our cohort, most patients with AM were administered CTX, whilst two patients underwent additional surgery.
Consequently, we only analysed the effect of metastasectomy on PMS for all patients rather than patients with AM only, revealing that surgery for metastases was associated with an improved outcome.
Due to the retrospective design of the study, not all questions can be answered, though, including the issue whether an earlier detection of AM would result in a survival benefit and at which frequency to perform abdominal ultrasound or CT-scans. These issues may be addressed in the frame of a prospective study, similar to the study by Puri et al, 26 
| 609
On the other hand, we were able to include a very large number of patients with eSTS, treated according to at the time current guidelines at experienced tertiary referral sarcoma centres, factors which we believe largely offset the impact of the above limitations. 
| CONCLUSIONS
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